Therapeutic targeting of the IL-13 pathway in skin inflammation
Por:
Tubau, C, Puig, L
Publicada:
2 ene 2021
Ahead of Print:
1 dic 2020
Resumen:
Introduction: Atopic dermatitis (AD) is a heterogeneous, chronic, inflammatory skin disease with a non-negligible prevalence at present. Its pathogenesis is complex, but mainly characterized by constitutive T helper type 2 (Th2)-cell activation. Systemic therapies for moderate-to-severe AD can be associated with adverse events that encumber their satisfactory long-term use. Several drugs targeting relevant molecules in the immunopathogenesis of AD have been approved or are under clinical development for the treatment of moderate to severe AD. To elaborate this review, literature searches were performed in PubMed on 29 August 2020.
Areas covered: This narrative literature review is focused on the pivotal role of IL-13 in the immunopathogenesis of AD and other skin diseases.
Expert opinion: Dupilumab has demonstrated the central role of IL-13 and IL-4 in the pathogenesis of AD, asthma, and other diseases in the atopic spectrum. In addition, phase III randomized clinical trials (RCTs) evaluating specific blockade of IL-13 with tralokinumab for treatment of AD also demonstrated favorable results, and phase III RCT evaluating lebrikizumab are ongoing. The role of IL-13 in other skin diseases should be further investigated.
Filiaciones:
Tubau, C:
Univ Autonoma Barcelona, Dermatol Dept, Hosp Santa Creu & St Pau, Barcelona 08041, Spain
Puig, L:
Univ Autonoma Barcelona, Dermatol Dept, Hosp Santa Creu & St Pau, Barcelona 08041, Spain
|